Dec 23, 2024 9:15am EST Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise
Nov 13, 2024 4:05pm EST Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates
Sep 25, 2024 4:05pm EDT Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates
Jul 22, 2024 7:00am EDT Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects
May 15, 2024 1:05pm EDT Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates
Feb 13, 2024 4:05pm EST Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates
Nov 14, 2023 4:05pm EST Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates
Oct 06, 2023 4:06pm EDT Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors
Sep 20, 2023 4:29pm EDT Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates
